A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

A high-throughput platform would greatly facilitate coronavirus disease 2019 (COVID-19) serological testing and antiviral screening. Here we present a high-throughput nanoluciferase severe respiratory syndrome coronavirus 2 (SARS-CoV-2-Nluc) that is genetically stable and replicates similarly to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xuping, Muruato, Antonio E., Zhang, Xianwen, Lokugamage, Kumari G., Fontes-Garfias, Camila R., Zou, Jing, Liu, Jianying, Ren, Ping, Balakrishnan, Mini, Cihlar, Tomas, Tseng, Chien-Te K., Makino, Shinji, Menachery, Vineet D., Bilello, John P., Shi, Pei-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567097/
https://www.ncbi.nlm.nih.gov/pubmed/33060595
http://dx.doi.org/10.1038/s41467-020-19055-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567097/
https://www.ncbi.nlm.nih.gov/pubmed/33060595
http://dx.doi.org/10.1038/s41467-020-19055-7

Ejemplares similares